Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

423 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study.
Shumilov E, Wurm-Kuczera R, Kerkhoff A, Wang M, Melchardt T, Holtick U, Bacher U, Staber PB, Mazzeo P, Leng C, Böckle D, Hölscher AS, Kauer J, Rotter N, Vucinic V, Rudzki JD, Nachbaur D, Bücklein VL, Schnetzke U, Krämer I, Wille K, Hasse A, von Tresckow B, Hänel M, Koenecke C, Velazquez GF, Viardot A, Schmid C, Thurner L, Wolf D, Subklewe M, Dreyling M, Dreger P, Dietrich S, Keller U, Jaeger U, Greil R, Pabst T, Lenz G, Chapuy B. Shumilov E, et al. Among authors: pabst t. Blood Adv. 2024 Dec 11:bloodadvances.2024014903. doi: 10.1182/bloodadvances.2024014903. Online ahead of print. Blood Adv. 2024. PMID: 39661985
Bridging radiotherapy before CAR-T therapy in CNS lymphoma.
Bacher U, Pabst T. Bacher U, et al. Among authors: pabst t. Blood Adv. 2024 Oct 8;8(19):5190-5191. doi: 10.1182/bloodadvances.2024013924. Blood Adv. 2024. PMID: 39378029 Free PMC article. No abstract available.
Boosting CAR T cells against lymphomas.
Pabst T, Bacher U. Pabst T, et al. Blood. 2024 Aug 15;144(7):689-691. doi: 10.1182/blood.2024025378. Blood. 2024. PMID: 39145947 No abstract available.
Blinatumomab in Relapsed/Refractory Burkitt Lymphoma.
Bohler J, Bacher U, Banz Y, Stadelmann R, Medinger M, Zander T, Pabst T. Bohler J, et al. Among authors: pabst t. Cancers (Basel). 2022 Dec 21;15(1):44. doi: 10.3390/cancers15010044. Cancers (Basel). 2022. PMID: 36612039 Free PMC article.
423 results